TrialSpark
New York, US · Delaware corporation · 7 known investors
Formation Bio develops drugs alongside research site partners, including health systems, academic medical centers, and independent research sites, with a focus on accelerating clinical trials in dermatology, rheumatology, and cardiometabolic diseases. The company provides technology solutions, monitoring services, and enrollment support to streamline the drug development process.
Founders & leadership
LZ
Linhao ZhangCo-Founder
BL
Benjamine LiuExecutive Officer, Director
AL
Alfred LinDirector
MM
Michael MoritzDirector
SK
Scott KuporDirector
Investors · 7
Andreessen Horowitz✓ verifiedMenlo Park · $500K – $50Mvia Scott Kupor · board
Sam Altman✓ verified
Section 32✓ verifiedPalo Alto
Sequoia Capital✓ verifiedMenlo Park · $4.4M – $214Mvia Michael Moritz · board
Thrive Capital✓ verifiedNew York · $500K – $25M
Mantis CapitalSanta Monica · $100K – $1M
Spark CapitalSan Francisco · $500K – $25M
Reported raises · per SEC filings
Form D private placements▶$372.2MraisedJul 2024 · 16 investors · PharmaceuticalsRule 506(b)
▶$372.2MraisedJul 2024 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Alfred LinDirector
- Linhao ZhangExecutive Officer, Director
- Michael MoritzDirector
- Scott KuporDirector
- Benjamine LiuExecutive Officer, Director
- Offering amount
- $512M
- Amount sold
- $372.2M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.